Financial Performance - The company achieved a revenue of CNY 2.133 billion in the first half of 2024, representing a year-on-year growth of 6.26% [2] - Net profit attributable to shareholders reached CNY 197 million, an increase of 12.61% compared to the same period last year [2] - Gross margin for blood glucose monitoring products was 61.32%, up by 5.16% year-on-year [3] Market Expansion - The company is focusing on expanding its blood glucose monitoring products in Southeast Asia, Africa, and the Middle East, with subsidiaries established in countries like Vietnam, the Philippines, and India [3] - The continuous glucose monitoring (CGM) system received EU MDR certification in September 2023, allowing sales in EU countries [3] - As of July 2024, the CGM product has been registered in multiple countries, including China, Indonesia, and several others [4] Strategic Focus - The company aims to maintain its core business in blood glucose monitoring while also developing chronic disease rapid testing [2] - Future strategies include enhancing the digital transformation of diabetes management and improving product registration planning in international markets [3][4] - The company plans to leverage cost advantages and industry chain strengths to penetrate the hospital market [6] Sales and Marketing - Sales expenses for the first half of 2024 were approximately CNY 556 million, a 16.54% increase year-on-year, primarily due to increased marketing efforts for the CGM product [7] - The domestic blood glucose market penetration rate has increased from 2% to 25%, indicating significant growth potential [7] - The company collaborates with over 3,500 hospitals nationwide, providing integrated blood glucose management systems [6]

Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Views - The company's H1 2024 performance met market expectations, with revenue of 2.133 billion yuan, a year-on-year increase of 6.26%, and a net profit of 197 million yuan, up 12.61% [1][2]. - The traditional blood glucose monitoring (BGM) business showed steady growth, with revenue of 1.552 billion yuan in H1 2024, reflecting a year-on-year increase of 12.74% [2]. - The Continuous Glucose Monitoring (CGM) products are expected to see significant sales growth, with a sales target of 300 to 500 million yuan for 2024 and potential profitability by 2025 [2]. - The company is positioned as a leading domestic player in the CGM market, having begun R&D in 2008 and recently launching new products [2]. - International expansion is anticipated, with the company aiming to enter major EU markets and submit an FDA application for its CGM products in 2024 [2]. Summary by Sections Financial Performance - H1 2024 revenue was 2.133 billion yuan, with a 6.26% increase year-on-year; Q2 revenue was 1.119 billion yuan, down 0.53% year-on-year [1]. - The net profit for H1 2024 was 197 million yuan, a 12.61% increase year-on-year, while Q2 net profit was 117 million yuan, up 0.78% year-on-year [1][2]. Business Segments - The BGM segment achieved revenue of 1.552 billion yuan in H1 2024, with a year-on-year growth of 12.74% [2]. - The CGM segment, which launched in 2023, is projected to generate sales of 300 to 500 million yuan in 2024, with expectations for profitability by 2025 [2]. International Expansion - The company has received CE certification for its CGM products and plans to enter major EU markets in 2024, with an FDA application submission also planned for 2024 [2]. - The overseas subsidiaries Trividia and PTS reported net profits of 31.22 million yuan and 9.27 million yuan, respectively, in H1 2024, indicating a positive trend in operations [2]. Earnings Forecast and Valuation - The forecast for net profit from 2024 to 2026 is 450 million yuan, 530 million yuan, and 630 million yuan, respectively [2]. - The company is recognized as the leading domestic brand in blood glucose monitoring, with promising international business prospects, justifying the "Buy" rating [2].

| --- | --- | --- | |---------------------------------------------------------------------------------------------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Insights - The company achieved a revenue of 2.133 billion RMB in the first half of 2024, representing a year-on-year increase of 6%. The net profit attributable to shareholders was 197 million RMB, up 13% year-on-year, while the non-recurring net profit decreased by 10% to 178 million RMB [2] - The blood glucose monitoring products showed stable growth with a significant increase in gross margin, reaching 61.32%, up 5.16 percentage points year-on-year. The company is focusing on both its core chronic disease rapid testing business and the growth of its Continuous Glucose Monitoring (CGM) products [2] - The company invested 171 million RMB in R&D, accounting for 8.02% of total revenue, indicating a commitment to innovation and product development [2] - The subsidiary Trividia showed improved profitability, contributing 543 million RMB in revenue and a net profit of 22.14 million RMB, benefiting from its FDA and CE certified products [2] Summary by Sections Performance Overview - In Q2 2024, the company reported revenue of 1.119 billion RMB, a slight decrease of 0.5% year-on-year, with a net profit of 117 million RMB, up 1% year-on-year. The non-recurring net profit fell by 25% to 101 million RMB [2] Revenue Breakdown - The blood glucose monitoring system generated 1.552 billion RMB in revenue, a year-on-year increase of 12.74%. Revenue by region includes 1.201 billion RMB from China (up 5.73%), 695 million RMB from the US (up 2.35%), and 237 million RMB from other regions (up 23.19%) [2] Future Projections - The company forecasts net profits of 470 million RMB, 635 million RMB, and 756 million RMB for 2024, 2025, and 2026 respectively, with growth rates of 65%, 35%, and 19% [2]

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, reaching RMB 1.2 billion, representing a year-on-year growth of 25%[1]. - The company's operating revenue for the first half of 2024 was CNY 2,133,039,651.44, representing a 6.26% increase compared to CNY 2,007,341,216.22 in the same period last year[12]. - The net profit attributable to shareholders for the same period was CNY 197,485,429.08, which is a 12.61% increase from CNY 175,368,479.46 in the previous year[12]. - Basic earnings per share increased by 13.06% to CNY 0.3558 from CNY 0.3147 in the previous year[12]. - The gross margin for the first half of 2024 improved to 45%, up from 40% in the same period last year[47]. - The company reported a significant reduction in financial expenses by 81.16%, down to ¥4,854,331.64 from ¥25,765,230.06, primarily due to the repayment of loans by a subsidiary[76]. - The company reported a total comprehensive income of CNY 184,062,165.69 for the first half of 2024, down from CNY 222,187,185.52 in the same period of 2023[166]. User Growth and Market Expansion - User data indicates that the number of active users of the blood glucose monitoring system has grown to 3 million, a 15% increase compared to the previous year[1]. - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 20% to 30%[1]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[1]. - The company has captured nearly 50% market share in the domestic blood glucose testing retail market, with over 22 million users and partnerships with more than 4,000 distributors and nearly 600 chain pharmacies[28]. - The company has established a global sales network covering 135 countries and regions, integrating overseas marketing channels through collaborative sales with subsidiaries PTS and Trividia[26]. Research and Development - Research and development expenses increased by 18%, reflecting the company's commitment to innovation and new technology[1]. - The company applied for 23 patents in the first half of 2024, including 5 invention patents, and received 14 new patent authorizations[34]. - The company is focused on integrating IoT and AI applications in its new product development, enhancing its R&D and manufacturing capabilities[37]. - The company is committed to ongoing research and development to expand its product offerings and improve patient outcomes in diabetes care and related health conditions[28][34]. Product Development and Innovation - New product launches include an advanced continuous glucose monitoring system, expected to enhance user experience and accuracy[1]. - The company has developed a multi-indicator testing product system that can currently detect over 70 indicators, expanding from a focus on blood glucose to include blood lipids, glycated hemoglobin, and more[21]. - The company introduced the iCARE-1300 portable multifunctional testing device, integrating three major testing modules to enhance diagnostic capabilities in grassroots medical institutions[33]. - The company launched the "San Nuo Ai Kan" continuous glucose monitoring system, which is the first third-generation sensor technology approved for sale in China, with a personal version MARD value of 8.71% and a hospital version MARD value of 7.45%[33]. - The company is expanding its product line with devices for monitoring blood glucose, blood ketone levels, and advanced glycation end products, enhancing its diabetes management offerings[15][16][18]. Strategic Acquisitions and Partnerships - The company is exploring strategic acquisitions to enhance its product portfolio and market reach[1]. - The company has established a strong collaboration with Trividia and PTS, enhancing global sales and supply chain resources[70]. - The company plans to pursue strategic acquisitions to bolster its product portfolio, aiming for at least two acquisitions by the end of 2024[46]. Risk Management and Compliance - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[1]. - The company is actively responding to industry policy changes and enhancing risk management capabilities to mitigate operational risks[99]. - The company emphasizes the importance of quality control and risk management to mitigate potential product liability issues as production scales up[97]. Corporate Governance and Social Responsibility - The company is committed to improving corporate governance and enhancing its ESG management practices to meet investor expectations[103]. - The company actively participates in social responsibility initiatives, donating medical devices to impoverished areas and supporting rural revitalization projects[119]. - The company emphasizes employee welfare by providing various non-monetary benefits, including meals, transportation, and recreational facilities[115]. Financial Management and Investments - The company has committed to invest RMB 975.95 million in various projects, with a cumulative investment of RMB 997.99 million as of the report date[90]. - The company has maintained compliance with regulations regarding the use of raised funds, ensuring prudent and scientific allocation[88]. - The company plans to ensure timely repayment of debts primarily through cash flows generated from its operating activities, indicating a proactive approach to financial management[154]. Employee Engagement and Development - The first phase of the employee stock ownership plan has been successfully implemented, aiming to align employee interests with company performance[1]. - The company has established a digital learning management platform to enhance employee training and development, facilitating clearer career paths[115]. - The company has established a comprehensive talent development system to support its organizational capabilities and foster employee growth[36].

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2024-058 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 第五届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"）第五届监事会第十次会议 于 2024 年 8 月 28 日（星期三）上午 11 时在公司会议室以现场方式召开。本次 会议的通知已于 2024 年 8 月 18 日通过书面或电子邮件方式送达全体监事。应出 席本次会议的监事 3 人，实际出席本次会议的监事 3 人，分别为欧阳柏伸先生、 陈春耕先生和黄绍波先生。本次会议由监事会主席欧阳柏伸先生召集并主持，公 司董事会秘书郑霁耘女士列席了会议。会议的召集、召开符合《公司法》及《公 司章程》、《公司监事会议事规则》的规定。 二、会议审议情况 （一）审议并通过《关于〈公司 2024 年半年度报告全文〉及其摘要的议案》 经审核，监事会认为：公司《2024 年半年度报告》、《 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 | 证券代码：300298 | 证券简称： | 三诺生物 | 公告编号：2024-061 | | --- | --- | --- | --- | | 债券代码：123090 | 债券简称： | 三诺转债 | | 三诺生物传感股份有限公司 关于"质量回报双提升"行动方案的公告 假记载、误导性陈述或重大遗漏。 2023 年 7 月 24 日，中共中央政治局会议明确提出"要活跃资本市场，提振 投资者信心"，2024 年 1 月 22 日，国务院常务会议强调"大力提升上市公司质 量和投资者价值，要采取更加有力有效措施，着力稳市场、稳信心"。为践行以 投资者为本的发展理念，增强投资者信心，促进公司长远健康可持续发展，三诺 生物传感股份有限公司（以下简称"公司"或"三诺生物"）围绕聚焦主业提升、 强化规范运作、坚持研发创新驱动、重视投资者回报和提升信息披露质量等方面， 制定了"质量回报双提升"行动方案。具体方案如下： 一、聚焦主业，力争成为全球领先的糖尿病数字管理专家 三诺生物成立于 2002 年 8 月，自创立以来，一直秉承"恪守承诺、奉献健 康"的企业 ...

三诺生物传感股份有限公司 2024年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：人民币万元 | | | 占用方与上市公 | 上市公司核算的 | 2024年期初占用资 | 2024年半年度占用累计 | 2024年半年度占用资 | 2024年半年度偿还 | 2024年6月末占用 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 司的关联关系 | 会计科目 | 金余额 | 发生金额（不含利息） | 金的利息（如有） | 累计发生金额 | 资金余额 | 占用形成原因 | 占用性质 | | 控股股东、实际控制 人及其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际控 制人及其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | - | - | | 其他关联方及附 属企业 | | | ...

三诺生物传感股份有限公司 2024年上半年募集资金存放与使用情况的专项报告 三诺生物传感股份有限公司（以下简称"公司"）根据中国证监会《上市公 司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等法律法规、规范性文件及相关格式指 引的规定，现将公司 2024 年上半年募集资金存放与使用情况报告如下： 一、募集资金基本情况 （一）募集资金金额及到账时间 1、2018年重组配套募集资金基本情况 经中国证券监督管理委员会核发的《关于核准三诺生物传感股份有限公司向 建投嘉孚（上海）投资有限公司等发行股份购买资产并募集配套资金的批复》【证 监许可﹝2018﹞38】号批准，公司获准非公开发行股份募集配套资金不超过 50,265 万元。公司根据发行方案已经实际向特定投资者非公开发行人民币普通股 （A 股）股票 27,987,193 股，发行价格为人民币 17.96 元/ 股，募集资金总额人 民币 502,649,986.28 元，扣除各项发行费用人民币 16,737,999. ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2024-057 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 第五届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （二）审议并通过《关于〈2024 年上半年募集资金存放与使用情况的专项 报告〉的议案》 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"）第五届董事会第十一次会 议于 2024 年 8 月 28 日（星期三）上午 10 时在公司会议室以现场结合通讯方式 召开。本次会议的通知已于 2024 年 8 月 18 日通过书面或电子邮件方式送达全体 董事。应出席本次会议的董事 7 人，实际出席本次会议的董事 7 人，分别为李少 波先生（兼任总经理）、李心一女士、车宏菁女士、李晖（LI HUI）先生、袁洪 先生、康熙雄先生、陈纪正女士。本次会议由董事长李少波先生召集并主持，公 司监事、高级管理人员列席了会议。会议的召集、召开符合《公司法》及《公司 章程》、《公司董事会议 ...